Global medical devices industry venture financing deals total $3.84bn in Q4 2020

Total medical devices industry venture financing deals in Q4 2020 worth $3.84bn were announced globally, according to GlobalData’s deals database.

The value marked a decrease of 17.7% over the previous quarter and a drop of 2.8% when compared with the last four-quarter average, which stood at $4bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $2.31bn. At the country level, the US topped the list in terms of deal value at $2.3bn.

In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Asia-Pacific and then Europe.

The top country in terms of venture financing deals activity in Q4 2020 was the US with 123 deals, followed by China with 51 and Switzerland with 11.

In 2020, as of the end of Q4 2020, medical devices venture financing deals worth $16.43bn were announced globally, marking an increase of 49.6% year on year

Medical devices industry venture financing deals in Q4 2020: Top deals

The top five medical devices industry venture financing deals accounted for 19% of the overall value during Q4 2020.

The combined value of the top five medical devices venture financing deals stood at $729m, against the overall value of $3.84bn recorded for the quarter.

The top five medical devices industry deals of Q4 2020 tracked by GlobalData were:

  • Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates’ $200m venture financing of Tempus Labs
  • The $150m venture financing of Singlera Genomics by CICC Kai Tak Fund, DETONG Capital Partners, FutureX Skyline Capital, Huamei International, Linden Asset Management, Prosperico Ventures, Proxima Ventures, Shanghai Free Trade Zone Fund Tao Capital, Shanghai Furong Investment, Shenzhen Green Pine Capital Partners and Wuxi Financial Investment
  • CCB International Capital, China International Capital, China Renaissance Holdings, China Structural Reform Fund, CICC Capital ManagementLimited, GL Ventures, Matrix Partners China and Taikang Asset Management’s $149m venture financing of GeneCast Biotechnology
  • The $120m venture financing of Cytek Biosciences by Hillhouse Capital Group, LYFE Capital, Orbimed Advisors and RA Capital Management
  • ACE &SA, Alychlo, aMoon Partners, Credit Suisse Group, Endeavour Vision, Eurazeo Growth, Famille C Invest, Generation Investment Management, Hitachi Ventures, Pictet & Cie Group and Swisscom Ventures’ venture financing of Sophia Genetics for $110m.

For more information 

To gain access to our latest press releases: GlobalData Media Centre 

Analysts are available for comment. Please contact the GlobalData Press Office:

EMEA & Americas: +44 207 936 6400

Asia-Pacific: +91 40 6616 6809 


For expert analysis on developments in your industry, please connect with us on: GlobalData | LinkedIn | Twitter 

Notes to Editors 

This analysis considers only announced and completed deals from the GlobalData financial deals database and exclude all terminated and rumored deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage. 

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources. 

About GlobalData 

4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis, and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, technology, energy, financial and professional services sectors

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button